NEW YORK (GenomeWeb) – N-of-One said today that it has signed a deal to provide copy number variation (CNV) analysis interpretation for customers of Affymetrix's OncoScan assay, which enables CNV measurements in solid tumor samples.
Financial terms of the arrangement were not disclosed.
"Affymetrix selected N-of-One because of their extensive experience delivering high quality clinical interpretation, which provides valuable insights to clinicians," Kim Caple, senior vice president and general manager of Affymetrix's clinical business, said in a statement. "The combination of [the] OncoScan assay and N-of-One interpretation will provide highly valuable intelligence to aid clinicians as they decide individual treatment options for their clinical research."
N-of-One has inked clinical interpretation service deals in recent months with the US Department of Veterans Affairs New England Veteran's Integrated Service Network, NeoGenomics, Intermountain Healthcare, and CeGaT.